How do compliance, convenience, and tolerability affect blood pressure goal rates?

American Journal of Cardiovascular Drugs

Volumn 12, Issue 5, 2012, Pages 295-302

  Erdine, Serap ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

antihypertensives; combination therapy.; Hypertension; patient compliance; treatment goals

Indexed keywords

AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN;

AGE; ANTIHYPERTENSIVE THERAPY; ASYMPTOMATIC DISEASE; ATTITUDE TO ILLNESS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; COGNITION; CORONARY ARTERY DISEASE; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GENDER; HEALTH CARE SYSTEM; HEART FAILURE; HUMAN; HYPERTENSION; KNOWLEDGE; PATIENT COMPLIANCE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TREATMENT WITHDRAWAL;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG COMBINATIONS; HUMANS; HYPERTENSION; MEDICATION ADHERENCE;

EID: 84866311561     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11635450-000000000-00000     Document Type: Review

References (61)

1. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 (9349): 1903-13
2. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105-87
3. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58
4. Pereira M, Lunet N, Azevedo A, et al. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009; 27 (5): 963-75
5. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007; 167 (2): 141-7
6. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressurerelated disease, 2001. Lancet 2008; 371 (9623): 1513-8
7. Allender S, Scarborough P, Peto V, et al. European cardiovascular disease statistics. 2008 10 July 2009 [online]. Available from URL: http://www.ehn heart.org/content/sectionintro.asp?level0=1457 [Accessed 2008]
8. Erdine S. Compliance with the treatment of hypertension: The potential of combination therapy. J Clin Hypertens (Greenwich) 2010; 12 (1): 40-6
9. WHO. Adherence to long-term therapies: Evidence for action [online]. Available from URL: http://wwwwhoint/chp/knowledge/publications/adherence-
10. full-reportpdf 2003 [Accessed 2010 Nov 22]
11. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117 (25): e510-26
12. Yiannakopoulou E, Papadopulos JS, Cokkinos DV, et al. Adherence to antihypertensive treatment: A critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005; 12 (3): 243-9
13. Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data. CMAJ 1999; 160 (1): 41-6
14. Mazzaglia G, Mantovani LG, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: A retrospective cohort study in primary care. J Hypertens 2005; 23 2093-2100
15. Krousel-Wood M, Thomas S, Muntner P, et al. Medication adherence: A key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004; 19 (4): 357-62
16. Richardson MA, Simons-Morton B, Annegers JF. Effect of perceived barriers on compliance with antihypertensive medication. Health Educ Q 1993; 20 (4): 489-503
17. Redon J, Brunner HR, Ferri C, et al. Practical solutions to the challenges of uncontrolled hypertension: A white paper. J Hypertens 2008; 26 (Suppl. 4): S1-14
18. Jacobs U, De Castro MS, Fuchs FD, et al. The influence of cognition, anxiety and psychiatric disorders over treatment adherence in uncontrolled hypertensive patients. PLoS ONE 2011; 6 (8): e22925
19. Journath G, Hellenius ML, Manhem K, et al. Association of physician's sex with risk factor control in treated hypertensive patients from Swedish primary healthcare. J Hypertens 2008; 26 (10): 2050-6
20. Osterberg L, Blaschke T. Adherence to medication.NEngl J Med 2005; 353 (5): 487-97
21. Bangalore S, Shahane A, Parkar S, et al. Compliance and fixed-dose combination therapy. Curr Hypertens Rep 2007; 9 (3): 184-9
22. Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin 2010; 26 (9): 2065-76
23. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43 (6): 521-30
24. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15
25. Kettani FZ, Dragomir A, Cote R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40 (1): 213-20
26. Perreault S, Dragomir A, Roy L, et al. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol 2010; 69 (1): 74-84
27. Perreault S, Dragomir A, White M, et al. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med 2009; 266 (2): 207-18
28. Dragomir A, Cote R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care 2010; 48 (5): 418-25
29. Halpern MT, Vincze GS, Stewart WF, et al. Persistence with hypertension therapy and long-term cardiovascular outcomes [abstract]. J Hypertens 2006; 24 (Suppl. 4): S182
30. Halpern MT, Vincze G, Stewart WF, et al. Compliance with hypertension therapy and long-term cardiovascular outcomes [abstract]. J Hypertens 2006; 24 (Suppl. 4): S154
31. Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12 (3): 239-45
32. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007; 64 (12): 1279-83
33. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med 2009; 122 (3): 290-300
34. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: D1665
35. Burnier M, Brown RE, Ong SH, et al. Issues in blood pressure control and the potential role of single-pill combination therapies. Int J Clin Pract 2009; 63 790-8
36. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 (9 Suppl.): 2-6
37. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002; 95 (1): 68-71
38. Wetzels GE, Nelemans P, Schouten JS, et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: A systematic review. J Hypertens 2004; 22 (10): 1849-55
39. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixeddose amlodipine besylate/benazepril HCl versus comparable componentbased therapy. Congest Heart Fail 2003; 9 (6): 324-32
40. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: A comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008; 8 (1): 45-50
41. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-analysis. Hypertension 2010; 55 (2): 399-407
42. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21 (5): 875-86
43. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003; 290 (21): 2805-16
44. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981-97
45. Wright Jr JT, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293 (13): 1595-608
46. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359 (23): 2417-28
47. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 2003; 326 (7404): 1427
48. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 (15): 1547-59
49. Kereiakes DJ, Neutel J, Stoakes KA, et al. The effects of an olmesartan medoxomil- based treatment algorithmon 24-hour blood pressure levels in elderly patients aged 65 and older. J Clin Hypertens (Greenwich) 2009; 11 (8): 411-21
50. Sellin L, Stegbauer J, Laeis P, et al. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-tomoderate hypertension. J Hypertens 2005; 23 (11): 2083-92
51. Punzi H, Neutel JM, Kereiakes DJ, et al. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: The AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther Adv Cardiovasc Dis 2010; 4 (4): 209-21
52. Rump LC, Girerd X, Sellin L, et al. Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. J Hum Hypertens 2011; 25 (9): 565-74
53. Chrysant SG, Oparil S, Melino M, et al. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich) 2009; 11;475-82
54. Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: An open-label, long-term study. Clin Drug Investig 2009; 29 (6): 381-91
55. Oparil S, Melino M, Lee J, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010; 32 (7): 1252-69
56. Calhoun DA, Lacourciere Y, Chiang YT, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: A randomized clinical trial. Hypertension 2009; 54 (1): 32-9
57. Izzo Jr JL, Chrysant SG, Kereiakes DJ, et al. 24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY ambulatory blood pressure substudy. J Clin Hypertens (Greenwich) 2011; 13 (12): 873-80
58. Chrysant S, Melino M, Fernandez V, et al. Efficacy and safety of combination olmesartan medoxomil (OM) besylate (AML) (HCTZ) in patients with hypertension: Analysis by age and gender. J Clin Hypertens 2010; 12 (Suppl. 1): A30-31
59. Oparil S, Chrysant SG, Melino M, et al. Long-term efficacy of a combination of amlodipine and olmesartan medoxomilhydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: A substudy of the COACH trial. J Hum Hypertens 2010; 24 (12): 831-8
60. Weir M, Hsueh WA, Nesbitt SD, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomilhydrochlorothiazide. J Clin Hypertens (Greenwich) 2011; 13 (6): 404-12
61. Jackson K, Brixner D, Oderda G, et al. Compliance and persistence of fixed dose versus free dose combination therapy with valsartan and HCTZ for patients with hypertension [abstract]. Value Health 2006; 9: A363